Clinical trials: HHT
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
This phase II trial studies the side effects and how well dalantercept works in treating patients with ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer that has returned.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01720173
- Testing
- Dalantercept, Laboratory Biomarker Analysis
- Where
- 40 sites in United States
- Volunteers
- 30 people
- Sponsor
- Gynecologic Oncology Group
Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is an observational registry of patients diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT).
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations, Telangiectasia, Epistaxis
- Trial name
- CHORUS (NCT06259292)
- Where
- 16 sites in United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Cure HHT
Hereditary Hemorrhagic Telangiectasia
Bevacizumab In Hereditary Hemorrhagic Telangiectasia
This research study is studying to see whether bevacizumab may treat chronic bleeding and iron deficiency anemia in Hereditary Hemorrhagic Telangiectasia (HHT).
- Trial name
- TrUST-HHT (NCT04404881)
- Testing
- Bevacizumab (Avastin®)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Hanny Al-Samkari, MD
Telangiectasia, Hereditary Hemorrhagic
Study of Histological Samples From Patients With Hereditary Haemorrhagic Telangiectasia
In this study the investigators will obtain histological samples from people with hereditary haemorrhagic telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome).
- Trial name
- NCT00733655
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Imperial College London
Hereditary Hemorrhagic Telangiectasia, Idiopathic Vascular Ectasia
Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study
This study will evaluate patients > 18 years of age with transfusion-dependent gastrointestinal bleeding due to documented gastrointestinal vascular ectasia with or without concurrent hereditary hemorrhagic telangiectasia (HHT).
- Trial name
- NCT02287558
- Testing
- Pomalidomide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The Cleveland Clinic
Hereditary Hemorrhagic Telangiectasia, Dental Diseases
Nationwide Awareness Campaign and Call for Dental Screening for HHT in Germany
HHT is a relative rare autosomal dominant inherited disorder of the fibrovascular tissue. Diagnosis of HHT is often delayed for decades (Pierucci 2012).
- Trial name
- NCT03549949
- Where
- Germany
- Volunteers
- 411 people, healthy volunteers welcome
- Sponsor
- University Hospital, Essen
Hereditary Hemorrhagic Telangiectasia (HHT)
Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study
This is a multicenter U.S. longitudinal study evaluating patients with hereditary hemorrhagic telangiectasia who participated in the PATH-HHT clinical trial of pomalidomide for the treatment of HHT.
- Trial name
- PATH-HHT ATLAS (NCT07018401)
- Testing
- Pomalidomide
- Where
- 11 sites in United States
- Volunteers
- 62 people
- Sponsor
- Massachusetts General Hospital
Hereditary Haemorrhagic Telangiectasia (HHT)
Immunmodulation in Patients With HHT
Hereditary haemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an inherited multisystemic disorder. Literature suggests that HHT is often associated with higher frequency of infectious diseases.
- Trial name
- NCT02983253
- Testing
- blood sample
- Where
- Germany
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- University Hospital, Essen
Hereditary Hemorrhagic Telangiectasia
Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
Hereditary hemorrhagic telangiectasia (HHT) is a hereditary vascular condition characterized by the development of abnormal connections between arteries and veins throughout the body, called vascular malformations.
- Trial name
- NCT01752049
- Testing
- Topical timolol maleate
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Unity Health Toronto
Telangiectasia, Hereditary Hemorrhagic, Osler-Rendu Disease
ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome
Scientific Objectives Primary objective : Demonstrate that oral intake of tranexamic acid significantly reduces the risk of epistaxis occurrence, estimated by the average monthly duration of episodes of epistaxis.
- Trial name
- NCT00355108
- Testing
- tranexamic acid
- Where
- France
- Volunteers
- 170 people
- Sponsor
- Hospices Civils de Lyon
Newly Diagnosed Acute Myeloid Leukemia With High Risk
HVA vs IA/DA or VA in the Treatment of ND HR-AML
The aim of this study is to evaluate the safety and efficacy of homohartonine combined with venetoclax and azacitidine (HVA) versus intensive chemotherapy (IA/DA) or venetoclax combined with azacitidine (VA) in newly diagnosed…
- Trial name
- NCT06810791
- Testing
- HVA, VA, Standard Chemotherapy
- Where
- China
- Volunteers
- 876 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hereditary Haemorrhagic Telangiectasia
Evaluation of Video-assisted Instructions of Nasal Self-packing in Patients with HHT
Inserting nasal self-packings is a secure method leaving patients more self-confident. We provide a video on https://www.youtube.com/watch?v=LaioLYfSJ-E demonstrating how to use nasal self-packings.
- Trial name
- NCT03841422
- Testing
- video-assisted nasal self-packing
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University Hospital, Essen
HHT
Tourniquet-Test in HHT
The Tourniquet test is used as a diagnostic procedure for thrombocytopathies and vascular diseases. Currently, there is no evidence whether this test is also positive in hereditary haemorrhagic telangiectasia (HHT), a…
- Trial name
- NCT06266624
- Testing
- Tourniquet Test
- Where
- Germany
- Volunteers
- 92 people
- Sponsor
- University Hospital, Essen
Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis
Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT)
Current management strategies for severe and recurrent epistaxis secondary to Hereditary hemorrhagic telangiectasia (HHT) include surgical procedures, and uncomfortable nasal packing, both of which are often only short-term…
- Trial name
- NCT02638012
- Testing
- Floseal, Packing
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Unity Health Toronto
Hereditary Hemorrhagic Telangiectasia, Epistaxis
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
During the Efficacy Study (Part B), the investigators will study whether Pazopanib, taken daily for 24 weeks, will reduce the severity of nose bleeds in patients with hereditary hemorrhagic telangiectasia (HHT).
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Epistaxis, Anemia, Nosebleed
- Trial name
- Paz (NCT03850964)
- Testing
- Pazopanib
- Where
- 11 sites in United States
- Volunteers
- 71 people
- Sponsor
- Cure HHT
Childhood Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Phase II trial to study the effectiveness of homoharringtonine in treating patients who have chronic phase chronic myelogenous leukemia.
- Conditions
- Childhood Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, Relapsing Chronic Myelogenous Leukemia
- Trial name
- NCT00006364
- Testing
- omacetaxine mepesuccinate, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
This phase II trial studies how well dalantercept works in treating patients with endometrial cancer that has come back or is persistent. Dalantercept may stop the growth of endometrial cancer by blocking blood flow to the tumor.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Mucinous Adenocarcinoma
- Trial name
- NCT01642082
- Testing
- Dalantercept, Laboratory Biomarker Analysis
- Where
- 30 sites in United States
- Volunteers
- 28 people
- Sponsor
- Gynecologic Oncology Group
Hereditary Hemorrhagic Telangiectasia, Epistaxis
Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary Hemorrhagic Telangiectasia (HHT) is a rare (~ 1/6000) but ubiquitous genetic disease. It is associated with abnormal angiogenesis and autosomal dominant inheritance, leading to telangiectasias and arteriovenous…
- Trial name
- ALEGORI (NCT02106520)
- Testing
- Bevacizumab
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Hospices Civils de Lyon
Hemorrhagic Hereditary Telangiectasia, HHT
Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH
Bevacizumab is widely prescribed for the treatment of severe bleeding related to epistaxis or gastrointestinal bleeding in HHT. We studied the efficacy of bevacizumab on severe bleeding in HHT patients in a randomized study…
- Trial name
- BEST (NCT06039124)
- Testing
- bevacizumab treatment
- Where
- 3 sites in France
- Volunteers
- 23 people
- Sponsor
- Hospices Civils de Lyon
Acute Myeloid Leukemia (AML)
Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)
This study is a single-arm, prospective, multi-center exploratory clinical trial. A total of 61 patients with newly diagnosed acute myeloid leukemia (AML) who are not suitable for intensive chemotherapy will be enrolled.
- Trial name
- VHAG (NCT07507825)
- Testing
- Intervention for Venetoclax, Intervention for Homoharringtonine, Intervention for Azacitidine
- Where
- China
- Volunteers
- 61 people
- Sponsor
- First People's Hospital of Hangzhou